Rapidly-Disintegrating Laminar Extrudates: Preliminary Experiments upon an Age Appropriate Pediatric Formulation

Original Citation:
Rapidly-Disintegrating Laminar Extrudates: Preliminary Experiments upon an Age Appropriate Pediatric Formulation / Perissutti, Beatrice; Zingone, Guglielmo; Lassiani, Lucia; Moneghini, Mariarosa; Franceschinis, Erica. - In: ANNALS OF PHARMACOLOGY AND PHARMACEUTICS. - ISSN 2573-6051. - ELETTRONICO. - 2:7(2017), pp. 1042.1-1042.6.

Availability:
This version is available at: 11577/3238999 since: 2017-07-18T08:39:58Z

Publisher:

Published version:
DOI:

Terms of use:
Open Access
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at http://www.unipd.it/download/file/fid/55401 (Italian only)

(Article begins on next page)
Rapidly-Disintegrating Laminar Extrudates: Preliminary Experiments upon an Age Appropriate Pediatric Formulation

B. Perissutti*, G. Zingone, L. Lassiani, M. Moneghini and E. Franceschinis

1Department of Chemical and Pharmaceutical Sciences, University of Trieste Italy
2Department of Pharmaceutical and Pharmacological Sciences, University of Padova, Italy

Abstract

The aim of the present investigation is to produce rapidly disintegrating laminar extrudates for delivering ibuprofen in the mouth of paediatric patients. This laminar shape is particularly convenient for drug delivering in the mouth and can be easily cut in different sizes allowing for a convenient adjustment of the drug dose depending on the age of the patient. Due to the fact that in paediatric formulations, the selection of the excipients is always a challenging issue and the reduction of their amount is always highly desirable, in this study to select the most appropriate composition to achieve a rapid disintegration and simultaneously permit a high amount of ibuprofen in the system, an experimental design for mixtures was employed and the disintegration time in simulated saliva was used as experimental response. In addition, after solid state analyses to check possible insurgence of drug-excipients interactions, laminar extrudates were characterised in terms of mechanical properties and in vitro dissolution performances. Extrudates with the desired uniform laminar shape, constant thickness (2 mm) and a very high content of drug (82% wt) were produced. These products exhibited a short disintegration time. The dose for a patient of 6-12 years corresponded to a length of extrudate between 1-1.5 cm, perfectly compatible with a formulation orodispersible thin laminar extrude intended for a paediatric patient (Figure 1).

Keywords: Paediatric formulation; Flexible formulation; Orodispersible formulation; Excipients; Disintegration

Introduction

The wet extrusion technology has long been known, but usually it represents an intermediate step which precedes the spheronization [1]. In this case it has been employed to prepare by wet extrusion an orodispersible ibuprofen paediatric formulation for patients aged 6-12 years, containing a dose of active ingredient of 100mg. These thin laminar extrudates are requested to accomplish various demands at the same time, such as rapid dispersion in the mouth, loading a dose of active principle in a piece of extruded compatible to a paediatric administration, the use of auxiliary components permitted for paediatric use and finally a high content of active principle and little amount of excipients (thus having less chance of toxicities or intolerance in young consumers) [2-5]. In this context, the extrusion process was chosen because it has the great advantage, compared to other technologies, to allow loading of high quantities of active principle. Moreover, the laminar shape of the extrusions that can be obtained in a single step from a rectangular die could allow an easy modulation of the ibuprofen dose depending on the age and weight of the patient simply varying the length of the extrudate. Further a laminar orodispersible extrudate have minimal impact on lifestyle and a reliable and convenient administration, as requested for an ideal formulation for children [6]. Not being commercially available orodispersible formulation prepared by wet extrusion, as a parameter of comparison, in all steps of research, a marketed formulation Nurofen® comprimés fondants 200 mg, oro-dispersible tablets available on the market in Belgium, was used. Further, due to the lack of characterizations for this innovative dosage form, alternative analyses used for the evaluation of films and orodispersible tablets or sublingual tablets were adapted and proposed.

Materials and Methods

Materials

Ibuprofen EP (IBU) (Acef), Crospovidone (Kollidon CL, Basf)- PVP-CL, Povidone (Kollidon, 

OPEN ACCESS

*Correspondence:
B Perissutti, Department of Chemical and Pharmaceutical Sciences, University of Trieste, Italy, Fax: +39 04052572; E-mail: bperissutti@units.it
Received Date: 11 Jan 2017
Accepted Date: 27 Feb 2017
Published Date: 01 Mar 2017

Citation:

Copyright © 2017 B.Perissutti. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Table 1: Pseudo mixture Experimental matrix.

<table>
<thead>
<tr>
<th>Exp.</th>
<th>Random sequence</th>
<th>MCC X1 (%)</th>
<th>PVP-CL X2 (%)</th>
<th>PVP X3 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>2</td>
<td>0</td>
<td>50</td>
<td>50</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>13,6</td>
<td>43,2</td>
<td>43,2</td>
</tr>
<tr>
<td>3</td>
<td>1</td>
<td>27,2</td>
<td>36,4</td>
<td>36,4</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>17,3</td>
<td>28,2</td>
<td>54,5</td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>11</td>
<td>54,5</td>
<td>34,5</td>
</tr>
<tr>
<td>6</td>
<td>7</td>
<td>17,3</td>
<td>54,5</td>
<td>28,2</td>
</tr>
<tr>
<td>7</td>
<td>5</td>
<td>11</td>
<td>34,5</td>
<td>54,5</td>
</tr>
</tbody>
</table>

BASF)-PVP, Microcrystalline cellulose (AvicelPh 101, FMC)- MCC, Aspartame - E 951(Acef), Polisorbate 80 (Montanox 80, Seppic) -E433 were used. Nurofen® comprimés fondants -200 mg (Reckitt Benckiser Healthcare- commercialized in Belgium) were used for comparison purposes as solid oro-dispersible dosage for containing ibuprofen. This formulation is indicated for children over the age of 12 years and for sale in Belgium. Nurofen comprimés fondants 200 mg contains in addition to 200 mg of active ingredient the following inactive ingredients: ethyl cellulose, precipitated silica, hypromellose, mannitol, aspartame (E951), Croscarmellose sodium, magnesium stearate, flavor (lemonor other). The total weight of the tablet is 700 mg, thus excipients represent 71.4% by weight.

Methods

Powder mixture composition and experimental design: The mixtures to be subjected to wet extrusion process were designed using experimental design for mixtures [7], using the software NEMRODW [8]. To reduce systematic errors, the extrusion tests were performed in randomized order. The mixture subjected to extrusion consists of five powder components (drug, microcrystalline cellulose, crospovidone, povidone) of which the active ingredient and the sweetener, which together accounted for 89% (w/w), were maintained in a constant quantity, while the proportions of the remaining three (together accounting 11% w/w) were varied to obtain even different pseudo-mixtures. The limits of each component in the pseudo-mixtures were defined during the preliminary trials obtaining the following values: for microcrystalline cellulose 0≤X1≤3, for crospovidone 3≤X2≤6, for povidone 3≤X3≤6 (%w/w in the mixture). For the palatability of the final formulation as partake was included in the fixed amount of 7% in the different mixtures with the rationale that for every 100 mg of ibuprofen are required 8.5 mg of aspartame for palatability of the final formulation, as in the marketed formulation chosen as a comparison (Nurofen comprimés fondants 200 mg). The experimental matrix is given in Table 1 and the experimental design space is depicted in Figure 2.

Wet Masses Preparation

One hundred batches of powders (active ingredient, sweetener and the three auxiliary excipients) were dry blended in a food mixer for 10 runs including 30 sec (mixing) and 1 minute (repose). The composition of the mixtures was in accordance to the proportions reported in Table 1, obtaining seven pseudo-mixtures. The mixtures were then wetted with 32% (w/w) of deionized water added with 1% of wetting agent while mixing. The kneading was carried out for further 10 minutes. The level of wetting was defined during the experimental tests. Evaluation of the content uniformity of the final extrudate established that the mixing had been successful. As wetting agent polysorbate 80 was selected from excipients acceptable in pediatric formulations and used at a low percentage, in consideration of the objective of reducing the toxicity of the final dosage form intended for a pediatric use. For clarity, Table 2 shows the composition of the final 7 mixtures. The dry mixtures were wetted with 32% demineralized water plus 1% of polysorbate 80 (w/w). Once produced, the mixtures were packaged in sealed bags and allowed to equilibrate for 24 h at room temperature, away from light and heat sources.

Extrusion Procedure

The laminar extrudates were prepared using a vertical lab scale ram extruder (Thalassia’, Trieste, Italy) described in details in a previous work [9]. Briefly, the movement of the stainless steel ram in this extruder is promoted by an oleo dynamic cylinder driven by an electric pump (max pressure 150 bar). The cylindrical nickel plated brass barrel, acting as a powder reservoir, has a capacity of 66 cm³ and an internal diameter of 25 mm. The die attached at the end of the barrel can be changed on demand: in this case a die with flat entry and rectangular shape (2 mm x 8 mm cross section) was used. The extruder chamber, thermo stated at 25°C, was loaded with 50 g of each mixture. The mass was forced through the die using a constant ram velocity. The obtained laminar extrudates were collected during the steady-state flow stage and deposited in trays covered with baking paper, and finally dried (in static oven) at 35°C until constant weight was achieved (4h). These drying parameters, chosen based on previous experience and according to the data of literature [10], did not influence the solid state characteristics of the blends, as assessed by DSC and PXRD analyses. Then, the laminar extrudates were sliced up in unities of length (1.5 cm) suitable to have 100 mg drug content and stored in well-closed bags for 7 days before characterizations.
Remedy Publications LLC.

Table 2: Composition of the wet masses (100 g powder plus 32 g water and 1 g surfactant).

<table>
<thead>
<tr>
<th>Exp.</th>
<th>MCC</th>
<th>PVP-CL</th>
<th>PVP</th>
<th>IBU</th>
<th>Aspartame</th>
<th>H2O</th>
<th>Surfactant</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>0</td>
<td>5.5</td>
<td>5.5</td>
<td>82</td>
<td>7</td>
<td>32</td>
<td>1</td>
</tr>
<tr>
<td>2</td>
<td>1</td>
<td>4.7</td>
<td>4.7</td>
<td>82</td>
<td>7</td>
<td>32</td>
<td>1</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>82</td>
<td>7</td>
<td>32</td>
<td>1</td>
</tr>
<tr>
<td>4</td>
<td>1.9</td>
<td>3.1</td>
<td>6</td>
<td>82</td>
<td>7</td>
<td>32</td>
<td>1</td>
</tr>
<tr>
<td>5</td>
<td>1.2</td>
<td>6</td>
<td>3.8</td>
<td>82</td>
<td>7</td>
<td>32</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>1.9</td>
<td>6</td>
<td>3.1</td>
<td>82</td>
<td>7</td>
<td>32</td>
<td>1</td>
</tr>
<tr>
<td>7</td>
<td>1.2</td>
<td>3.8</td>
<td>6</td>
<td>82</td>
<td>7</td>
<td>32</td>
<td>1</td>
</tr>
</tbody>
</table>

Wettability Measurements

In order to assess the effect of the addition of surfactant on the Wettability of the active substance ibuprofen, which represents 82% w/w of the formulations and therefore is by far the predominant component, the contact angle was measured. This evaluation was carried out according to the drop method on compressed non-disintegrating disks, using deionized water as a wetting liquid. Two types of compacts were subjected to this test: tablets of ibuprofen wetted by a) deionized water (32% w/w) and b) deionized water (32% w/w) plus 1% of polysorbate 80. Disks were prepared compressing the mixtures in a manual press Perkin Elmer, imparting a force of 5 tons for 1 minute. After compression, the tablets were dried at 40°C using the same procedure as the extrudates. The flat tablets produced were then analyzed with the Drop Shape Analysis System (Krüss DSA 30), using as a wetting solution 5 ml of purified water. The contact angle measurement, performed in triplicate was performed after 10 seconds.

Characterisations of the Laminar Extrudates

Solid state analyses

Thermal analyses were conducted using a differential scanning calorimeter DSC Mettler TA 4000 (Greifensee, Switzerland) connected to a cell Mettler DSC20 calorimeter, equipped software STaRe software version 9.30. The analysis was conducted on fragments of extruded, on the raw materials and physical mixtures prepared in the same weight ratios of the systems obtained by extrusion. The samples were subjected to a dynamic heating speed of 10°C / min in a temperature range between 25 and 200°C in air atmosphere. Furthermore, a STOE D500 diffractometer (Siemens, Monaco) was employed, analysing samples in the range of angle at atmosphere. Furthermore, a STOE D500 diffractometer (Siemens, Monaco) was employed, analysing samples in the range of angle at atmosphere. Furthermore, a STOE D500 diffractometer (Siemens, Monaco) was employed, analysing samples in the range of angle at atmosphere.

Disintegration Tests

The disintegration test (observed response Y) was conducted in a modified USP disintegration test, using 10 ml of pH 6.8 buffer as a medium (simulated saliva), since the classical EP method (employing 900 ml of disaggregation medium) is not adequate to simulate the mouth cavity environment and to test orodispersible formulations. In short, the method used consisted of a beaker glass of 25 ml containing 5 ml of phosphate buffer, subjected to the same agitation and heating (temperature-controlled bath at 37°C) of the USP disintegrating apparatus (Erweka ZT3, Eusenstamm, Germany). The extrudates were observed during the analyses, and their time of disaggregation was counted using a stopwatch. The analysis was repeated six times for each sample, always using as a comparison specialty commercial Nurofen® comprimés fondants 200 mg.

Attempts to impart the extruded during the disintegration test at a pressure similar to that exerted by the tongue were unsuccessful, since the calibrated weight (100 g) cylinder, positioned over the laminar extrudate, excluded the monitoring of the disintegration time.

Stimulated Wetting Test

To evaluate the ability of hydration over time of the extruded samples, simulating their behavior when in direct contact with saliva, extruded samples of about 1.5 cm (equal to 100 mg of ibuprofen) from each mixture were cut, carefully weighed, and subjected to the method reported in the literature [11-13]. In short, the fragments of extruded were placed in a tray covered by a layer of absorbent paper (size 11x7 cm) impregnated with phosphate buffer (acting as a tongue), and on the top covered with two layers of absorbent paper impregnated of phosphate buffer (simulating the palate). At fixed times (15, 30, 45, 60, 75, 90, 105, 120 seconds) fragments were collected and weighed by calculating the percentage of hydration at various times with the following formula (eq.1):

\[ W = \frac{\text{wet weight} - \text{dry weight}}{\text{dry weight}} \times 100 \]  

(eq. 1)

For every time point the three samples of each mixture were tested.

In vitro Drug Dissolution

The in vitro ibuprofen dissolution studies were performed using the method proposed for sublingual tablets by Rachid et al. [12]. The dissolution medium consisted in 5 ml of pH 6.8 phosphate buffer (prepared with 4.33 g of K2HPO4 and 3.39 g KH2PO4), thermostated at 37°C. Samples of extruded containing 100 mg of ibuprofen (suitable dose for children aged 6-12 years) and approximately 1-1.5 cm in length, were placed on the filter (porosity 0.45 µM) and covered with buffer solution. At each time point, the vacuum pump (KNF Laboprt - Neueberg) was activated to allow the removal (in the tube below the vacuum filter) of the solution containing the drug dissolved. The times selected, by virtue of the presence of orodispersible formulation in the mouth, were the following: 15, 30, 45, 60, 90, 120 seconds (6 time points). The analysis was conducted in threefold repetition: for each distinct time point 3 pieces of laminar extrudates of the same mixture were taken. The dissolution medium was then filtered and assayed spectrophotometrically (after appropriate dilution with phosphate buffer thermostated at 37°C, if necessary) at 223 nm (Spettrofotometer Biochron Libra S12, Cambridge, UK). For comparison, dosage units of oro-dispersible Nurofen® comprimés
fondants 200 mg were therefore divided into halves (to get the same dose of active ingredient) and subjected to the same analysis. Given the small number of samples (3 repetitions for each time point) statistical analysis of the data were not carried out.

**Results and Discussion**

The objective of this study was to obtain by wet extrusion an orodispersible dosage form containing ibuprofen intended to patients aged between 6 and 12 years. Not being orodispersible extrudates available on the market, as a comparison parameter, in every step aged between 6 and 12 years. Not being orodispersible extrudates orodispersible dosage form containing ibuprofen intended to patients.

The extrusion was preferred over other techniques because innovative and because it allows to incorporate high amounts of active principle up to a maximum of 90% in the final product [1]. Furthermore, this technology enables to obtain, through appropriate selection of the die, a shape suitable to administration in the mouth. In this research it was chosen a rectangular die allowing to obtain a thin laminar shape of extrudates, having thickness of 2 mm, width of 8 mm and length that can be chosen according to the desired dose (and, in this case, to the patient’s age). The small thickness of the extrudatespresumably consents an easy dispersion in the mouth. In order to reduce as much as possible the amount of other ingredients in the final dosage form, thus limiting the possibility of adverse reactions by the same auxiliary components, it would be highly desired that such formulations provide a high drug loading. Furthermore, due to the goal of rapid dispersions in the mouth, such formulations must contemplate the presence of disintegrating excipients that favour the disintegration of the solid form in the mouth cavity. Finally, in this preliminary study, for the palatability of the final formulation, being an orodispersible formulation and ibuprofen a well- known bad tasting drug [14-16], Aspartamewasincluded in the fixed amount of 7% in the different mixtures with the rationale that for every 100 mg of ibuprofen is required 8.5 mg of aspartame, as in the marketed formulation chosen as a comparison. In view of its well-known toxicity [17] the idea is to replace it in a subesquent study. First preliminary tests were carried out in order to define the optimal quantity and composition of the binder solution, usually ranging about 32-40% w/w [1]. The powder masses were composed of ibuprofen and microcrystalline cellulose, the most classical diluent/binder for wet extrusion [1]. During such preliminary tests it was noted that with a 37-40% water content, the masses showed insufficient consistency and irregular shape as they flowed out of the die at very low pressures, while masses containing less than 32% water were not sufficiently plastic to be extruded (the extrusion process required higher pressures than those permitted from the apparatus) or togive origin to regular extrudates (e.g. sharkskin defects, surface cracks or fractures). Then several disintegrants, such as cross linked corn carmellose sodium (AcidiSol® FMC, Bruxelles, B), Soy polysaccharides (Emcosoy® STS IP, JRS Pharma Rosenberg, DE), sodium starch glicolate (Explotab™, JRS Pharma, Rosenberg, DE) and crospovidone were tested in association with high percentages of ibuprofen (superior to 80%). In the selection of such excipients the disintegrant ability and attitude to wet extrusion process of classical synthetic excipients (such as crospovidone) was compared with that of other ingredients of natural or semi-synthetic origin, that are commonly preferred in formulations for children by paediatricians and from the market. At the end of such screening, however, only crospovidone resulted capable of forming extrudates having regular shape and smooth surface, while permitting a rapid disintegration in water. During preliminary trials the following limits of the 3 above mentioned excipients in the pseudo-mixtures were defined: for microcrystalline cellulose 0≤X ≤3, for crospovidone 3≤X ≤6, for povidone 3≤X ≤6 (% w/win the mixture). It is interesting to note that the presence of microcrystalline cellulose was found not mandatory for the extrusion process, opening the possibility to further reduce the number of included excipients, and to prevent delay of disintegration due to the presence of microcrystalline cellulose. Also during preliminary trials, the addition of 1% surfactant in the binder solution was found to be necessary to achieve a rapidly disintegrating product. This was due to the fact that ibuprofen, which represents 82% w/w of the formulations and therefore is by far the predominant component, is a hydrophobic powder [18]. The addition of 1% polysorbate the binder solution determined a remarkable reduction of mean contact angle: pure ibuprofen was 77.05±7.09°, whilst after addition of 1% polisorbate 80 the value diminished to

---

**Table 3: Characterization results of the laminar extrudates and reference formulation.**

<table>
<thead>
<tr>
<th>Sample</th>
<th>Thickness (mm) (mean ± SD, n=10)</th>
<th>Hardness (N) (n=10)</th>
<th>Percent drug content (mean ± SD, n=3)</th>
<th>Loading efficiency (%) (mean ± SD, n=3)</th>
<th>Disintegration time (sec) (mean±SD, n=6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1.85 ± 0.18 &lt;10 N</td>
<td>89.3 ± 5.5</td>
<td>111.3 ± 3.0</td>
<td>151 ± 8</td>
<td>17 ± 3</td>
</tr>
<tr>
<td>2</td>
<td>1.9± 0.13 &lt;10 N</td>
<td>86.02 ± 6.0</td>
<td>113 ± 7.0</td>
<td>73 ± 17</td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>2.03±0.16 &lt;10 N</td>
<td>93.9 ± 7.0</td>
<td>114.5 ± 8.2</td>
<td>187 ± 24</td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>1.9± 0.13 &lt;10 N</td>
<td>96.7 ± 4.0</td>
<td>118 ± 4.5</td>
<td>85 ± 8</td>
<td></td>
</tr>
<tr>
<td>5</td>
<td>2.3±0.12 &lt;10 N</td>
<td>91 ± 8.4</td>
<td>111 ± 10.3</td>
<td>88 ± 10</td>
<td></td>
</tr>
<tr>
<td>6</td>
<td>1.9±0.13 &lt;10 N</td>
<td>86.6 ± 5.0</td>
<td>95.3 ± 4.0</td>
<td>32 ± 7</td>
<td></td>
</tr>
<tr>
<td>7</td>
<td>2.19±0.16 &lt;10 N</td>
<td>95.5 ± 1.3</td>
<td>116.5 ± 1.6</td>
<td>21 ± 4</td>
<td></td>
</tr>
<tr>
<td>Reference formulation</td>
<td>&lt;10 N n.d.</td>
<td>n.d.</td>
<td>n.d.</td>
<td>39 ± 12</td>
<td></td>
</tr>
</tbody>
</table>
51.55±5.35 (mean ± SD, n = 3). Extrudates with the desired uniform laminar shape, constant thickness (2 mm) and a very high content of drug (82% wt) were produced with all the compositions (Table 3). The thickness varies very little from the dimensions of the die, demonstrating the absence of phenomena of expansion after the exit from the die or deformation while drying or over storage. The recorded values are affected by the composition of the mixture and are reproducible within batches with the same composition. The dimensions are compatible with the objective of administration in the mouth and promising for the purposes of dispersion in the mouth itself. The dose for a patient of 6-12 years (100 mg) corresponded to a length of extrudate between 1-1.5 cm, perfectly compatible with a formulation orodispensible thin lamellar extrudate intended for a paediatric patient. At the end of the selection of the excipients, the physical compatibility between the drug and excipients was check for any interactions that could occur between components during the various processing steps. Extruded samples were analysed by DSC and PXRD, in comparison with the same physical mixtures having ratios by weight active principle/excipients and with the individual raw materials. Again, due to comparative purposes the physical mixture was subjected to an isothermal heating simulating drying conditions and then analysed by DSC and PXRD. The results of the PXRD (Figure 2) and DSC analyses (data not shown for brevity) agreed to attest the absence of interactions and significant changes in the solid state of the active ingredient by simply mixing, or as a result of the process drying or extrusion. As it can be seen from disintegration tests, the addition of surfactant permitted to the lamellar system (having a very high content of drug) to be homogeneously wetted, thus reaching crospovidone particles and allowing for rapid disintegration. The most rapid systems disintegrated in less than 30 sec. The lamellar extrudates disintegrated with different disintegration times, depending on their composition, and the disintegration time was in some cases comparable to that of the marketed formulation (around 30 sec). This result is particularly significant when taking into account that these extrudates contain a very high amount of active ingredient, whereas the reference contains the 28.6% of drug. The effect of varying percentage of individual components in mixtures on the disintegration time in pH 6.8 buffer were evaluated graphically by use of the program NEMRODW, considering the disintegration time as experimental response (Figure 3). Disintegration time decreased as the amount of crospovidone increased, and as the amount of cellulose diminished. To go into more details, from the graphical evaluation of the effect on the disintegration time of the percentage of the individual components on mixtures wetted with 1% polysorbate 80 the following considerations can be drawn: the higher the content of povidone and crospovidone in mixtures, extrudates break up in less time, while increasing the proportion of microcrystalline cellulose in mixtures there has been a slowdown in disintegration, as expected from a diluent/binder insoluble in water [19]. Looking at the slope of the three lines, each corresponding to the percentage of a component, a greater influence of the percentage of microcrystalline cellulose than the other two excipients may be observed. The composition of the extruded demonstrating the best disintegration time in the group was: in addition to the fixed amounts of 82% of API and 7% of aspartame, 6% of crospovidone (limit of experimental plan) and 1.9% of microcrystalline cellulose and 3.1% of PVP. By assessing the disintegration time in light of the other performed characterizations (results reported in Table 3), it can be seen how the disintegration is not dependent on the thickness nor the hardness of the extrudates. No correlation between the above properties and disintegration was noticed. In fact, while the disintegration varies significantly from sample to sample, the thickness and the breaking load (less than 10 N in all cases) are quite similar. The composition of the extrudates appears therefore primarily responsible for the different performance. In order to assess the ability of such dosage forms hydrate when in contact with small amounts of water, a method proposed in the literature and in the case of lamellar extrudate [11], sublingual [12] and orodispensible preparations [13] was used. The results of this test are reported in Figure 4, where it can be observed that water absorption varies between 3 and 25%. The samples that showed a greater absorption of water corresponded to samples with lower disintegration time. Such amount of water absorbed (3-25%) are perfectly compatible with the small amounts of hydrophilic colloids, able to swell and absorb water present in the extruded and are always able to determine the fragmentation extrudate in the mouth. As expected, the commercial sample containing rather large amounts of hydrophilic agents, e.g. croscarmellose sodium, absorbed much greater amounts of water. The correspondence between simulated wetting time and disintegration time proved that this was due to the time required for water to diffuse through the whole extrude, rather than the hardness of the extrudates, that was found in all case very scarce (Table 3). Finally, in order to evaluate the release of active ingredient from the formulation in the short time of stay in the mouth, and then predict whether the active ingredient can be dissolved in the saliva and be available for absorption, in vitro dissolution test was carried out. Although it was not a goal of the research, the absorption of a certain percentage of the dose of active principle before swallowing would allow a quick pharmacological onset and would partly bypass the gastro-intestinal tract. In addition, knowledge of drug dissolution in
the saliva is an important finding to design the subsequent study of taste-masking formulation of the extrudate. Sample 7 showing the shortest disintegration time in each set was selected cut in fragments having a content of 100 mg of active and subjected to in vitro dissolution test according to the method proposed by Rachid et al. [12]. Reference tablets, divided in halves (to have the same content of active principle), were also tested in analogous conditions. The results (Figure 5) proved that a certain amount of ibuprofen (about 5%) is released, and hence available for absorption, from the extrudates in less than 2 minutes (average time of permanence of a orodispersible formulation in the mouth) thanks to the hydrophilic components of the formulation and the presence of the surfactant, despite the poor solubility of the active principle.

**Conclusion**

Rapidly–disintegrating laminar extrudates, easy to be cut in different lengths allowing for a convenient adjustment of the drug dose, can be a viable and age appropriate formulation to deliver ibuprofen in children. These systems offer several advantages, including the easy administration without need of water, the use of very little amounts of excipients (18% by wt) per each drug dose, the easy dose adjustment depending on the age of the patient.

**References**